Phase 1b Study Of The mdm2 Antagonist rg7112 In Combination With 2 Doses/Schedules Of Cytarabine Karen Yee, md



Download 15,83 Kb.
Sana08.06.2017
Hajmi15,83 Kb.
#10608
Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine

Karen Yee, MD1*, Giovanni Martinelli, MD2, Sarit Assouline3, Margaret Kasner, MD4, Norbert Vey, MD PhD5*, Kevin R. Kelly, MD, PhD6, Mark W. Drummond, PhD, FRCPath, MB, CHB7, Michael Dennis, FRCP, FRCPath8*, Karen Seiter, MD9, Steven Blotner, PhD10*, Lori Jukofsky11*, Steven Middleton, PhD12*, Jianguo Zhi, PhD13*, Gong Chen, PhD14*, Hua Zhong, PhD15* and Gwen Nichols, MD13

1Princess Margaret Hospital, Toronto, ON, Canada; 2Department of Hematology and Oncological Sciences “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy; 3Jewish General Hospital, Montreal, QC, Canada; 4Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; 5Hematology department, Institut Paoli Calmettes, Marseille, France;6University of Texas Health Science Center at San Antonio, CTRC Institute for Drug Development, San Antonio, TX; 7Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; 8Haematology, Christie NHS Foundation Trust, Manchester, United Kingdom; 9New York Medical College, Valhalla, NY; 10Biostatistics, Hoffmann-LaRoche, Inc, Nutley, NJ;11Hoffmann-LaRoche, Nutley, NJ; 12Research and Early Development, Hoffmann-LaRoche, Inc, Nutley, NJ; 13Research and Early Development, Hoffmann-LaRoche, Nutley, NJ;14Bioinformatics, Hoffmann-La Roche, Nutley, NJ; 15Bioinformatics, Hoffman-La Roche, Nutley, NJ

Background: Activation of the p53 pathway through inhibition of its negative regulator MDM2 is a promising strategy for cancer therapy. Phase 1 results in AML with RG7112, a small-molecule antagonist of MDM2, demonstrated single-agent activity, including complete responses (CRs) (ASH 2012). Here we report results of a Phase 1b trial of RG7112 in combination with Ara-C in pts with AML.

Methods: This is a multicenter, open-label phase 1b study of pts with AML treated with escalating oral doses of RG7112 in 2 arms.  Arm A: pts unsuitable for standard (re)induction, treated with RG7112 and Ara-C 20 mg/m2 SC both daily × 10 days every 28 days; arm B: relapsed/refractory pts treated with RG7112 × 5 days and Ara-C 1 g/m2 IV × 6 days every 28 days. Primary objectives were to determine MTD and DLTs; secondary objectives were pharmacokinetics (PK), pharmacodynamics, and clinical responses. Blood and bone marrow were collected for PK and biomarker analyses pre- and at multiple on-treatment time points. Mutations in TP53 were detected using the PCR- and microarray-based AmpliChip p53 research test, detecting single-nucleotide alterations of exons 2-11. Pharmacodynamic markers of p53 activation included serum MIC-1 measured by ELISA, and MDM2gene expression by RT-PCR.

Results: Enrollment is complete with forty-three pts treated (16 arm A, 27 arm B) with escalating doses of RG7112.  3 DLTs included rash and prolonged thrombocytopenia (Arm B) and diarrhea (Arm A).  MTD was 1000 mg bid × 10 days (arm A) and 1500 mg bid x 5 days (arm B) based on prolonged cytopenias. PK (Cmax, AUC, and Ctrough) data were comparable with historic monotherapies, suggesting no drug-drug interactions. Adverse events (> 20%) were GI or infectious.

Clinical activity: Arm A: median age 70 y, median prior therapies 1. During the initial safety period 2 pts died (ARDS, sepsis).  See table for results for the 14 pts completing cycle 1. CRs (21%) occurred at 1g and 2g of RG7112 in pts with no prior therapy or HU.   ORR (CR,PR, SD/HI) was 43%.

Arm B: median age 50 y, median prior therapies 3 (all relapsed after Ara-C). During the initial safety period 4 pts died of sepsis (1 complicated by multi-organ failure). See table for results for the 23 pts completing cycle 1.  CRs (17%) were observed in patients refractory to DA, and MEC (2) or HiDAc (1) and occurred at RG7112 doses >2g/d.  ORR  was 52%.  Three pts bridged to transplant (1 CR, 2 HI).



Evaluable patient characteristics by response to treatment

Arm A (N = 14)*

Best response

 3 CR

0 PR

3 SD/HI

8 PD

TP53 status

All WT

-

All WT

3 mutant, 5 WT

Cytogenetics (responders)

2 nl, 1 complex

 

 

 

 

 

 

 

 

Arm B (N = 23)*

Best Response

2 CR, 1 CRi, 1 CRp

1 PR

(extramedullary relapse)



7 SD/HI

11 PD

(after 1-2 cycles)



TP53 status

All WT

 

1 mutant

1 mutant, 10 WT

Cytogenetics (responders)

2 nl, 1 complex, 1 unknown prior MDS, 1 del 7

1 nl

 

 

 

 

 

 

 

Abbreviations:  CRi, complete remission with incomplete recovery; CRp, complete remission with incomplete platelet recovery; PR, Partial Response; SD, Stable Disease; HI, Hematologic Improvement; HU, Hydroxyurea; PD, Progressive Disease; Nl, Normal Karyotype; DA, Daunorubicin and Ara-C; MEC, Mitoxantrone, Etoposide, and Ara-C; HiDAc, High dose intermittent Ara-C; AZA, Azacitidine; MDS, myelodysplastic syndromes.  *Two continue on therapy as of July 2013

Biomarker activity:  MIC-1 induction was similar to RG7112 monotherapy.  Preliminary data demonstrated increased MDM2 expression on day 2, consistent with the MoA (p53 activation and associated feedback) previously reported (Ray-Coquard, 2012). TP53 activation did not consistently correlate with clinical activity, implying factors downstream of functional p53 may be critical for activity. Additionally, a predictive mRNA signature that significantly correlates with RG7112 efficacy in cell lines and in phase 1 AML pt samples (Spearman correlation, 0.6; P= 0.0009; manuscript in preparation) was prospectively evaluated in this study.



Conclusions: Here we report the safety and clinical activity of an MDM2 antagonist in combination with Ara-C in pts with AML. CRs in elderly and heavily pretreated pts refractory to cytarabine-containing regimens were observed. Pharmacodynamic activity of the p53 pathway was demonstrated by increases in MIC-1 and MDM2 expression. Results of ongoing biomarker analyses to predict response for future development will be reported.
Download 15,83 Kb.

Do'stlaringiz bilan baham:




Ma'lumotlar bazasi mualliflik huquqi bilan himoyalangan ©hozir.org 2024
ma'muriyatiga murojaat qiling

kiriting | ro'yxatdan o'tish
    Bosh sahifa
юртда тантана
Боғда битган
Бугун юртда
Эшитганлар жилманглар
Эшитмадим деманглар
битган бодомлар
Yangiariq tumani
qitish marakazi
Raqamli texnologiyalar
ilishida muhokamadan
tasdiqqa tavsiya
tavsiya etilgan
iqtisodiyot kafedrasi
steiermarkischen landesregierung
asarlaringizni yuboring
o'zingizning asarlaringizni
Iltimos faqat
faqat o'zingizning
steierm rkischen
landesregierung fachabteilung
rkischen landesregierung
hamshira loyihasi
loyihasi mavsum
faolyatining oqibatlari
asosiy adabiyotlar
fakulteti ahborot
ahborot havfsizligi
havfsizligi kafedrasi
fanidan bo’yicha
fakulteti iqtisodiyot
boshqaruv fakulteti
chiqarishda boshqaruv
ishlab chiqarishda
iqtisodiyot fakultet
multiservis tarmoqlari
fanidan asosiy
Uzbek fanidan
mavzulari potok
asosidagi multiservis
'aliyyil a'ziym
billahil 'aliyyil
illaa billahil
quvvata illaa
falah' deganida
Kompyuter savodxonligi
bo’yicha mustaqil
'alal falah'
Hayya 'alal
'alas soloh
Hayya 'alas
mavsum boyicha


yuklab olish